The incidence of drug-induced liver injury (DILI) has been increasing year by year and has risen to the fifth leading cause of death due to liver diseases globally. Liver injury caused by anti-tumor drugs accounts for 20%-25% of DILI. China is a country with a high incidence of malignant tumors, and the incidence of tumors has shown an upward trend in recent years. Chemotherapy is currently one of
Conditions
Interventions
Treatment group for 8 weeks:None
Treatment group for 4 weeks:None
Treatment group for 12 weeks:None
Initial treatment group:None
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Voluntarily sign the informed consent form; 2.The age ranges from 16 to 65 years old. 3.Newly diagnosed tumor patients who are planned to receive targeted and immunotherapy; 4.Have good compliance and be able to take medications as per the protocol and attend follow-up appointments on schedule.
Exclusion criteria
Exclusion criteria: 1.The age is less than 18 years old or more than 65 years old. 2.The liver function indicators had already shown abnormalities before receiving targeted and immunotherapy; 3.Use drugs with obvious liver damage (such as antituberculosis drugs, anti-HIV drugs, non-steroidal anti-inflammatory drugs, etc.) after the liver function test and before chemotherapy. 4.Use drugs with obvious liver damage in combination (such as antituberculosis drugs, anti-HIV drugs, non-steroidal anti-inflammatory drugs, etc.); 5.Combined with other liver treatments (such as liver radiotherapy, transarterial hepatic embolization treatment, etc.); 6.The follow-up period is less than 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver biochemical index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Economic burden; | — |
Countries
China
Contacts
Public ContactYingli He
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed